

Ramon E Parsons

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5581230/publications.pdf>

Version: 2024-02-01

129
papers

39,704
citations

20817

60
h-index

15266

126
g-index

132
all docs

132
docs citations

132
times ranked

30393
citing authors

#	ARTICLE	IF	CITATIONS
1	WAF1, a potential mediator of p53 tumor suppression. <i>Cell</i> , 1993, 75, 817-825.	28.9	8,091
2	<i>PTEN</i> , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer. <i>Science</i> , 1997, 275, 1943-1947.	12.6	4,506
3	Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. <i>Cell</i> , 1993, 75, 1215-1225.	28.9	2,195
4	Inactivation of the Type II TGF- β Receptor in Colon Cancer Cells with Microsatellite Instability. <i>Science</i> , 1995, 268, 1336-1338.	12.6	2,173
5	Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. <i>Nature Genetics</i> , 1997, 16, 64-67.	21.4	1,902
6	Inhibition of Cell Migration, Spreading, and Focal Adhesions by Tumor Suppressor PTEN. <i>Science</i> , 1998, 280, 1614-1617.	12.6	1,113
7	The Molecular Basis of Turcot's Syndrome. <i>New England Journal of Medicine</i> , 1995, 332, 839-847.	27.0	1,060
8	Hypermutability and mismatch repair deficiency in RER+ tumor cells. <i>Cell</i> , 1993, 75, 1227-1236.	28.9	1,031
9	Mutation of <i>Pten/Mmac1</i> in mice causes neoplasia in multiple organ systems. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 1563-1568.	7.1	912
10	Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. <i>Nature Medicine</i> , 1996, 2, 169-174.	30.7	892
11	PIK3CA Mutations Correlate with Hormone Receptors, Node Metastasis, and ERBB2, and Are Mutually Exclusive with PTEN Loss in Human Breast Carcinoma. <i>Cancer Research</i> , 2005, 65, 2554-2559.	0.9	813
12	Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. <i>Nature Medicine</i> , 2007, 13, 1203-1210.	30.7	804
13	P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 9052-9057.	7.1	765
14	Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. <i>Nature Genetics</i> , 1995, 9, 48-55.	21.4	759
15	Germline mutations in PTEN are present in Bannayan-Zonana syndrome. <i>Nature Genetics</i> , 1997, 16, 333-334.	21.4	622
16	PTEN: Life as a Tumor Suppressor. <i>Experimental Cell Research</i> , 2001, 264, 29-41.	2.6	606
17	An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in <i>Pten</i> ^{+/-} mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 10320-10325.	7.1	582
18	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. <i>Human Molecular Genetics</i> , 1998, 7, 507-515.	2.9	578

#	ARTICLE	IF	CITATIONS
19	Mutations of <i>hTERT</i> in Genetically Unstable Cells. <i>Science</i> , 1995, 268, 1915-1917.	12.6	476
20	Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 7564-7569.	7.1	445
21	Genetic instability occurs in the majority of young patients with colorectal cancer. <i>Nature Medicine</i> , 1995, 1, 348-352.	30.7	355
22	The role of PTEN signaling perturbations in cancer and in targeted therapy. <i>Oncogene</i> , 2008, 27, 5477-5485.	5.9	338
23	Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. <i>Nature Genetics</i> , 2008, 40, 102-107.	21.4	316
24	PTEN: from pathology to biology. <i>Trends in Cell Biology</i> , 2003, 13, 478-483.	7.9	314
25	Lack of PTEN sequesters CHK1 and initiates genetic instability. <i>Cancer Cell</i> , 2005, 7, 193-204.	16.8	305
26	Mismatch repair deficiency in phenotypically normal human cells. <i>Science</i> , 1995, 268, 738-740.	12.6	304
27	PTEN mutations in gliomas and glioneuronal tumors. <i>Oncogene</i> , 1998, 16, 2259-2264.	5.9	300
28	Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 2884-2889.	7.1	295
29	Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 11563-11568.	7.1	291
30	Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 16224-16229.	7.1	285
31	A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival. <i>Science</i> , 2013, 341, 399-402.	12.6	270
32	Distinct IL-2 Receptor Signaling Pattern in CD4 ⁺ CD25 ⁺ Regulatory T Cells. <i>Journal of Immunology</i> , 2004, 172, 5287-5296.	0.8	241
33	PTEN function: the long and the short of it. <i>Trends in Biochemical Sciences</i> , 2014, 39, 183-190.	7.5	231
34	Activation of the PI3K Pathway in Cancer Through Inhibition of PTEN by Exchange Factor P-REX2a. <i>Science</i> , 2009, 325, 1261-1265.	12.6	228
35	PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. <i>Genes and Development</i> , 2005, 19, 1662-1667.	5.9	214
36	Cell type-specific DNA methylation patterns in the human breast. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 14076-14081.	7.1	210

#	ARTICLE	IF	CITATIONS
37	Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. <i>Cancer Cell</i> , 2015, 27, 837-851.	16.8	205
38	Human cancer, PTEN and the PI-3 kinase pathway. <i>Seminars in Cell and Developmental Biology</i> , 2004, 15, 171-176.	5.0	197
39	Identification of the Rac-GEF P-Rex1 as an Essential Mediator of ErbB Signaling in Breast Cancer. <i>Molecular Cell</i> , 2010, 40, 877-892.	9.7	194
40	Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. <i>Oncogene</i> , 1998, 16, 3215-3218.	5.9	175
41	The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration. <i>Cancer Research</i> , 2008, 68, 1862-1871.	0.9	149
42	Discovery of a first-in-class EZH2 selective degrader. <i>Nature Chemical Biology</i> , 2020, 16, 214-222.	8.0	148
43	HLTF gene silencing in human colon cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 4562-4567.	7.1	145
44	Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. <i>Neuro-Oncology</i> , 2007, 9, 271-279.	1.2	144
45	BAF180 Is a Critical Regulator of p21 Induction and a Tumor Suppressor Mutated in Breast Cancer. <i>Cancer Research</i> , 2008, 68, 1667-1674.	0.9	143
46	Hypomorphic Mutation of PDK1 Suppresses Tumorigenesis in PTEN+/+ Mice. <i>Current Biology</i> , 2005, 15, 1839-1846.	3.9	141
47	Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 1455-1460.	7.1	134
48	PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. <i>Oncogene</i> , 2008, 27, 4657-4665.	5.9	131
49	3-Phosphoinositide-Dependent Kinase 1 Potentiates Upstream Lesions on the Phosphatidylinositol 3-Kinase Pathway in Breast Carcinoma. <i>Cancer Research</i> , 2009, 69, 6299-6306.	0.9	126
50	Reduced expression of PTEN correlates with breast cancer progression. <i>Human Pathology</i> , 2002, 33, 405-409.	2.0	123
51	Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. <i>Cell Cycle</i> , 2009, 8, 2198-2210.	2.6	107
52	Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas. <i>Oncogene</i> , 1998, 17, 123-127.	5.9	99
53	PTEN Loss Inhibits CHK1 to Cause Double Stranded-DNA Breaks in Cells. <i>Cell Cycle</i> , 2005, 4, 927-929.	2.6	95
54	Cbx8 Acts Non-canonically with Wdr5 to Promote Mammary Tumorigenesis. <i>Cell Reports</i> , 2016, 16, 472-486.	6.4	95

#	ARTICLE	IF	CITATIONS
55	PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2017, 7, 380-390.	9.4	94
56	The New York Cancer Project: Rationale, Organization, Design, and Baseline Characteristics. <i>Journal of Urban Health</i> , 2004, 81, 301-310.	3.6	83
57	Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. <i>BMC Molecular Biology</i> , 2001, 2, 2.	3.0	78
58	Mutational analysis of the PTEN gene in head and neck squamous cell carcinoma. , 1998, 77, 684-688.		77
59	Pten (phosphatase and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. <i>Diabetologia</i> , 2007, 50, 395-403.	6.3	71
60	Gab2-Mediated Signaling Promotes Melanoma Metastasis. <i>American Journal of Pathology</i> , 2009, 174, 1524-1533.	3.8	67
61	DNA Mismatch Repair Deficiency Accelerates Endometrial Tumorigenesis in Pten Heterozygous Mice. <i>American Journal of Pathology</i> , 2002, 160, 1481-1486.	3.8	65
62	RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation. <i>Cell Research</i> , 2013, 23, 552-564.	12.0	65
63	HIN-1, an Inhibitor of Cell Growth, Invasion, and AKT Activation. <i>Cancer Research</i> , 2005, 65, 9659-9669.	0.9	61
64	Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 155-160.	7.1	61
65	Phosphatases and tumorigenesis. <i>Current Opinion in Oncology</i> , 1998, 10, 88.	2.4	60
66	Loss of PTEN Expression Is Associated with Poor Prognosis in Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Clinical Cancer Research</i> , 2013, 19, 6830-6841.	7.0	60
67	PTEN Expression Causes Feedback Upregulation of Insulin Receptor Substrate 2. <i>Molecular and Cellular Biology</i> , 2001, 21, 3947-3958.	2.3	59
68	Analysis of the PTEN gene in human meningiomas. <i>Neuropathology and Applied Neurobiology</i> , 1998, 24, 3-8.	3.2	55
69	PTEN and Cancer. , 2003, 222, 147-166.		55
70	PTEN inhibits PREX2-catalyzed activation of RAC1 to restrain tumor cell invasion. <i>Science Signaling</i> , 2015, 8, ra32.	3.6	53
71	Augmented Stat5 Signaling Bypasses Multiple Impediments to Lactogen-Mediated Proliferation in Human β^2 -Cells. <i>Diabetes</i> , 2015, 64, 3784-3797.	0.6	52
72	10q23.3 loss of heterozygosity is higher in lymph node-positive (PT2-3,N+) versus lymph node-negative (PT2-3,N0) prostate cancer. <i>Human Pathology</i> , 2000, 31, 504-508.	2.0	51

#	ARTICLE	IF	CITATIONS
73	p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes. <i>Molecular Cancer Research</i> , 2017, 15, 1051-1062.	3.4	51
74	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. <i>Science Signaling</i> , 2014, 7, pe15.	3.6	50
75	Cooperation Between Distinct Cancer Driver Genes Underlies Intertumor Heterogeneity in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2020, 159, 2203-2220.e14.	1.3	47
76	Analysis of PTEN mutations and deletions in B-cell non-Hodgkin's lymphomas. <i>Genes Chromosomes and Cancer</i> , 1999, 24, 322-327.	2.8	46
77	Cystic Fibrosis Transmembrane Conductance Regulator Attaches Tumor Suppressor PTEN to the Membrane and Promotes Anti <i>Pseudomonas aeruginosa</i> Immunity. <i>Immunity</i> , 2017, 47, 1169-1181.e7.	14.3	45
78	Phosphatase and Tensin Homolog Regulation of Islet Growth and Glucose Homeostasis. <i>Journal of Biological Chemistry</i> , 2005, 280, 39388-39393.	3.4	44
79	Metformin and erlotinib synergize to inhibit basal breast cancer. <i>Oncotarget</i> , 2014, 5, 10503-10517.	1.8	44
80	Is the small heat shock protein β -crystallin an oncogene?. <i>Journal of Clinical Investigation</i> , 2005, 116, 30-32.	8.2	43
81	Survival factor NFIL3 restricts FOXO-induced gene expression in cancer. <i>Genes and Development</i> , 2013, 27, 916-927.	5.9	42
82	PTEN Loss Promotes Mitochondrially Dependent Type II Fas-Induced Apoptosis via PEA-15. <i>Molecular and Cellular Biology</i> , 2009, 29, 1222-1234.	2.3	41
83	Molecular Pathways: Intercellular PTEN and the Potential of PTEN Restoration Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5379-5383.	7.0	40
84	Molecular Pathways: Targeting the PI3K Pathway in Cancer – BET Inhibitors to the Rescue. <i>Clinical Cancer Research</i> , 2016, 22, 2605-2610.	7.0	37
85	New Frontiers for the NFIL3 bZIP Transcription Factor in Cancer, Metabolism and Beyond. <i>Discoveries</i> , 2014, 2, e15.	2.3	32
86	A new class of cancer-associated PTEN mutations defined by membrane translocation defects. <i>Oncogene</i> , 2015, 34, 3737-3743.	5.9	32
87	AKT Degradation Selectively Inhibits the Growth of PI3K/PTEN Pathway – Mutant Cancers with Wild-Type KRAS and BRAF by Destabilizing Aurora Kinase B. <i>Cancer Discovery</i> , 2021, 11, 3064-3089.	9.4	32
88	Reduction of <i>Pten</i> dose leads to neoplastic development in multiple organs of <i>Pten</i> ^{shRNA} mice. <i>Cancer Biology and Therapy</i> , 2010, 10, 1194-1200.	3.4	31
89	Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. <i>Translational Oncology</i> , 2017, 10, 357-366.	3.7	31
90	Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT Oncogenes. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a036129.	6.2	30

#	ARTICLE	IF	CITATIONS
91	Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. <i>Cancer Biology and Therapy</i> , 2013, 14, 246-253.	3.4	29
92	Differential subtraction chain, a method for identifying differences in genomic DNA and mRNA. <i>Nucleic Acids Research</i> , 1999, 27, 24e-24.	14.5	27
93	Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degradable. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 18054-18081.	6.4	27
94	Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. <i>BMC Cancer</i> , 2016, 16, 587.	2.6	26
95	Microarray analysis of gliomas reveals chromosomal position-associated gene expression patterns and identifies potential immunotherapy targets. <i>Journal of Neuro-Oncology</i> , 2007, 85, 11-24.	2.9	25
96	PTEN interacts with the transcription machinery on chromatin and regulates RNA polymerase II-mediated transcription. <i>Nucleic Acids Research</i> , 2019, 47, 5573-5586.	14.5	24
97	Irs2 Inactivation Suppresses Tumor Progression in Pten+/- Mice. <i>American Journal of Pathology</i> , 2009, 174, 276-286.	3.8	22
98	PREX1 Protein Function Is Negatively Regulated Downstream of Receptor Tyrosine Kinase Activation by p21-activated Kinases (PAKs). <i>Journal of Biological Chemistry</i> , 2016, 291, 20042-20054.	3.4	20
99	Mouse ER+/PIK3CAH1047R breast cancers caused by exogenous estrogen are heterogeneously dependent on estrogen and undergo BIM-dependent apoptosis with BH3 and PI3K agents. <i>Oncogene</i> , 2019, 38, 47-59.	5.9	20
100	Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degradable via Structure-Activity Relationship Studies. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 3644-3666.	6.4	20
101	PTEN and NEDD4 in Human Breast Carcinoma. <i>Pathology and Oncology Research</i> , 2016, 22, 41-47.	1.9	19
102	The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer. <i>Oncogene</i> , 2005, 24, 2735-2738.	5.9	16
103	NOTCH and EZH2 collaborate to repress PTEN expression in breast cancer. <i>Communications Biology</i> , 2021, 4, 312.	4.4	16
104	p21-activated Kinases (PAKs) Mediate the Phosphorylation of PREX2 Protein to Initiate Feedback Inhibition of Rac1 GTPase. <i>Journal of Biological Chemistry</i> , 2015, 290, 28915-28931.	3.4	14
105	Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma. <i>Cell Reports</i> , 2022, 39, 110637.	6.4	12
106	Two somatic biallelic lesions within and near SMAD4 in a human breast cancer cell line. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 372-383.	2.8	11
107	Physiological levels of PTEN control the size of the cellular Ins(1,3,4,5,6)P5 pool. <i>Cellular Signalling</i> , 2006, 18, 488-498.	3.6	11
108	Analysis of intracellular PTEN signaling and secretion. <i>Methods</i> , 2015, 77-78, 164-171.	3.8	11

#	ARTICLE	IF	CITATIONS
109	The side-chain cleavage of cholesterol sulfateâ€™II. The effect of phospholipids on the oxidation of the sterol sulfate by inner mitochondrial membranes and by a reconstituted cholesterol desmolase system. The Journal of Steroid Biochemistry, 1985, 23, 313-321.	1.1	10
110	Phosphatidylinositol 3-Kinase Inhibitors Are a Triple Threat to Ovarian Cancer: Fig. 1.. Clinical Cancer Research, 2005, 11, 7965-7966.	7.0	10
111	mTOR Inhibition, the Second Generation: ATP-Competitive mTOR Inhibitor Initiates Unexpected Receptor Tyrosine Kinaseâ€™Driven Feedback Loop. Cancer Discovery, 2011, 1, 203-204.	9.4	10
112	<i>PIK3CA</i> and <i>p53</i> Mutations Promote 4NQO-Initiated Head and Neck Tumor Progression and Metastasis in Mice. Molecular Cancer Research, 2020, 18, 822-834.	3.4	10
113	Limited Mitochondrial Activity Coupled With Strong Expression of CD34, CD90 and EPCR Determines the Functional Fitness of ex vivo Expanded Human Hematopoietic Stem Cells. Frontiers in Cell and Developmental Biology, 2020, 8, 592348.	3.7	8
114	Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma. Molecular Cancer Research, 2022, 20, 1193-1207.	3.4	7
115	Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 718-723.	3.9	6
116	The side-chain cleavage of cholesterol sulfateâ€™III. the effect of adrenodoxin, membrane phospholipids and tween 80 on the kinetics of oxidation of the sterol sulfate by a reconstituted cholesterol desmolase system. The Journal of Steroid Biochemistry, 1986, 24, 909-916.	1.1	5
117	Analysis of PTEN Mutation in Non-familial Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 317-331.	3.8	5
118	Ten Essential Practices for Developing or Reforming a Biostatistics Core for a NCI Designated Cancer Center. JNCI Cancer Spectrum, 2018, 2, pky010.	2.9	5
119	Abnormal elevated PTEN expression in the mouse antrum of a model of GIST KitK641E/K641E. Cellular Signalling, 2011, 23, 1857-1868.	3.6	4
120	Restoring tumor suppression. Science, 2019, 364, 633-634.	12.6	4
121	Pathology and genetic testing. Cancer, 1997, 80, 636-648.	4.1	2
122	Defining Variations in Survival of BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2011, 306, 1597.	7.4	2
123	Mutational Loss of PTEN Induces Resistance to NOTCH1 Inhibition in T-ALL. Blood, 2007, 110, 5-5.	1.4	2
124	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. Frontiers in Medicine, 2022, 9, 849222.	2.6	2
125	Molecular genetics and hereditary cancer. Cancer, 1997, 80, 533-536.	4.1	1
126	PREX2, a new breed of cancer gene with too many spots?. Pigment Cell and Melanoma Research, 2012, 25, 409-410.	3.3	1

#	ARTICLE	IF	CITATIONS
127	Machine Learning Approaches for Early Prostate Cancer Prediction Based on Healthcare Utilization Patterns. <i>Studies in Health Technology and Informatics</i> , 2022, 289, 65-68.	0.3	1
128	The Oncogenetic Basis of Breast Cancer. , 2005, , 15-26.		0
129	Abstract IA012: Recent progress with PTEN. , 2021, , .		0